Loren Data's SAM Daily™

FBO DAILY - FEDBIZOPPS ISSUE OF APRIL 01, 2015 FBO #4876
SOLICITATION NOTICE

R -- The pilot program will focus on improving patient use and outcomes of prescription medications for DoD beneficiaries.

Notice Date

3/30/2015
 

Notice Type

Presolicitation
 

NAICS

621399 — Offices of All Other Miscellaneous Health Practitioners
 

Contracting Office

Other Defense Agencies, Defense Health Agency, Contract Operations Division - Falls Church, 7700 Arlington Blvd., Suite 1M401, Falls Church, Virginia, 22042, United States
 

ZIP Code

22042
 

Solicitation Number

HT001115RFIMEDICALTHERAPYMANAGEMENT(MTM)
 

Point of Contact

Ronald L. Hyde, Phone: 7036815396, Vonetta R. Davis,
 

E-Mail Address

ronald.l.hyde.ctr@mail.mil, vonetta.davis.ctr@dha.mil
(ronald.l.hyde.ctr@mail.mil, vonetta.davis.ctr@dha.mil)
 

Small Business Set-Aside

N/A
 

Description

Request for Information Title: Implementation of Medication Therapy Management (MTM) in the Department of Defense Pilot Program RFI #: HT001115RFIMEDICATIONTHERAPYMANAGEMENT(MTM) Introduction: 1. This announcement constitutes a Request for Information (RFI). This announcement does not constitute a commitment, implied or otherwise that a solicitation will be issued. This is not a request for proposal (RFP) or an invitation for bids (IFB). 2. Please note that the collection of this requested information does not obligate the U.S. Government to incorporate any solicited comments nor does it obligate the Government to procure the services. Proprietary information should not be included in the RFI response. Responses to this RFI will not be returned. The Government is not liable to pay any costs associated with companies responding to this RFI. 3. All information received resulting from this RFI will be used by the Defense Health Agency (DHA) for acquisition planning and market research purposes only. However, your response may be releasable to the public under the Freedom of Information Act (FOIA). If you wish the DHA to consider any portion of your response as “confidential commercial information”, you should clearly mark the portion as “confidential commercial information”. 4. The Defense Health Agency (DHA), at its discretion, may request respondents to this RFI to elaborate on information in their written response. Respondents to this RFI will not be notified of any results derived from a review of the information provided. 5. The DHA invites all interested parties to submit a written response to this Request for Information (RFI). This RFI is issued for the sole purpose of conducting market research in accordance with the Federal Acquisition Regulation (FAR) Part 10. Background The National Defense Authorization Act of 2015, under Section 726 mandates a pilot program to assess MTM under the TRICARE program. The pilot program will focus on improving patient use and outcomes of prescription medications for DoD beneficiaries. It will include patients with more than one chronic medical condition and taking more than one medication. The pilot will run for not less than two years. The provision requires that not less than three location types be included in the program. a. One location will be military medical treatment facilities (MTFs) where beneficiaries receive care under the current Patient Centered Medical Home (PCMH) model. b. The second location will provide MTM in MTFs to beneficiaries receiving primary care services from providers outside the MTF. c. The third location will be a pharmacy other than the MTF. Statement of Capability 1. The Government is interested in gaining insight on commercial best practices for the delivery of Medication Therapy Management (MTM) and to assist the Department of Defense (DoD) in structuring a pilot program as required in NDAA 2015. As a result, the DHA is performing market research to ascertain interest, capabilities, and available solutions within healthcare industry to address areas of defining the process, training, documenting patient encounters, measuring and analyzing data, and promoting an MTM program. Interested parties are asked to submit information which includes but is not limited to the following commercial best practices for the implementation: a. Projected timeline for the implementation of the pilot to include the details below in b through k. b. Based on your capabilities, methods, and recommendations, please define the MTM process and assessment of a successful process: i. describe characteristics or conditions of an MTM program which are identified with a high degree of success or higher rate of failure; ii. identify a hierarchy of disease states most responsive to MTM; iii. describe measures used to determine success in improving medication use; iv. describe how the effects of an MTM program can be quantified to assess the cost of care; and v. define success of a program at the humanistic, economic and system levels. regarding the pharmacy staffing model for each location type described above, to deliver MTM. Method of MTM service delivery could include but is not limited to services rendered: i. in person either at the pharmacy or in a clinic setting; ii. telephonic methods; and iii. video teleconferencing and other methods. d. Describe your capability, methods and/or industry practice for training for current and future staff with emphasis on industry best practices for the delivery of MTM care. This should include but is not limited to: i. objectives of training plan relevant to MTM outcome; ii. length of training for pharmacists; iii. areas on which training will focus; iv. how pharmacist skills will be assessed; and v. measures to ensure training objectives are met and can be linked to an MTM outcome. e. Describe your capability or industry technologies for documenting patient interactions. Technology features should include, but is not limited to: i. methods which the patient interaction will be documented; ii. methods of capturing information to effectively measure programs; iii. examples of remote tracking; iv. methods for reviewing and analyzing data to evaluate the program; and v. define parameters used to evaluate the success of the program at the humanistic, economic and system levels. f. Describe your capability and/or recommendations on methods to measure the program at the patient, pharmacist, clinic, treatment facility, and enterprise-wide level. g. Describe your capability and/or recommendations on methods to maximize patient use of the services available. h. Describe your capability and/or recommendations on methods to maximize acceptance of the program among other clinical staff. i. Describe your capability and recommendations on the use of pharmacists in the inpatient setting to facilitate Transition of Care. j. Describe your approach to and/or considerations on program variations that are dependent on the varied sites described above, where service is rendered. k. Describe any other valuable features that should be included in the DoD MTM program from lessons learned during previous MTM project deployments and suggest new approaches or proven processes of MTM. Information Submission Instructions: The Government encourages responses from interested parties who are capable of responding to the entire scope of the RFI, as well as interested parties who may have specific expertise in only limited areas of this RFI. Respondents are advised that the Government will not pay for any information or administrative costs incurred in response to this RFI. All costs associated with responding to this RFI will be solely at the responding party’s expense. Proprietary information may be submitted; however, interested parties are responsible for adequately marking proprietary, restricted or competition sensitive information contained in their response. Proper restrictions shall be marked as such on each page. Only the Government will review this RFI. Interested qualified interested parties, small or large organization, should submit information for this request. The information should not to exceed fifteen (15) single side pages, using 12 point Arial font. An additional ten (10) pages of other materials (e.g., graphs, tables, figures) may be submitted. All responses should be submitted using PDF, HTML, MS Word or PowerPoint formats with subject "RFI MTM Pilot. Only electronic submissions will be accepted. Electronic files larger than 10 MB should be broken down into multiple files with no one (1) file exceeding 10 MB. Each electronic submission shall include: a) RFI number and “RFI MTM Pilot” in the subject line. b) If the submission includes more than one (1) electronic email, the file number and total files being submitted (e.g., File 1 of 4, File 2 of 4, etc.) in the subject line. c) A brief summary of the email’s content, the vendor’s name, and mailing address. All responses to the RFI must be submitted electronically (via e-mail) to: Robert LeBlanc, at the following email addresses:robert.e.leblanc6.civ and Ronald Hyde at ronald.l.hyde.ctr@mail.mil, no later than 1:00 pm EST, on May 1 2015. Receipt time will be determined by the recorded time of receipt in the Contract Officer’s email box. In the event submissions include multiple electronic files, all files must be received in the electronic mail box by the due date specified above to be considered timely..
 

Web Link

FBO.gov Permalink
(https://www.fbo.gov/notices/f149f97cbd95f329ffd125cccce6b113)
 

Place of Performance

Address: 7700 Arlington Blvd., Falls Church, Virginia, 22402, United States

Zip Code: 22402
 

Record

SN03683239-W 20150401/150330235109-f149f97cbd95f329ffd125cccce6b113 (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |